MX2022005949A - Anticuerpos anti-ror-2 y metodos de uso. - Google Patents

Anticuerpos anti-ror-2 y metodos de uso.

Info

Publication number
MX2022005949A
MX2022005949A MX2022005949A MX2022005949A MX2022005949A MX 2022005949 A MX2022005949 A MX 2022005949A MX 2022005949 A MX2022005949 A MX 2022005949A MX 2022005949 A MX2022005949 A MX 2022005949A MX 2022005949 A MX2022005949 A MX 2022005949A
Authority
MX
Mexico
Prior art keywords
antibodies
ror2
inter alia
antibody compositions
ror
Prior art date
Application number
MX2022005949A
Other languages
English (en)
Inventor
Thomas J Kipps
I Widhopf George F I
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MX2022005949A publication Critical patent/MX2022005949A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/50—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Abstract

En la presente se proporcionan, entre otros, anticuerpos (por ejemplo, anticuerpos humanizados, anticuerpos monoclonales), fragmentos de anticuerpos (por ejemplo, scFv) y composiciones de anticuerpos (por ejemplo, receptores de antígeno quimérico, anticuerpos biespecíficos), que se unen a receptor 2 poco frecuente similar a tirosina quinasa (ROR2) humano con alta eficacia y especificidad. Los anticuerpos y las composiciones de anticuerpo proporcionados en la presente incluyen novedosas CDR de dominio de cadena liviana y pesada y regiones marco y son, entre otros, útiles para diagnosticar y tratar cáncer y otras enfermedades relacionadas con ROR2.
MX2022005949A 2019-11-18 2020-11-18 Anticuerpos anti-ror-2 y metodos de uso. MX2022005949A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962936900P 2019-11-18 2019-11-18
PCT/US2020/061130 WO2021102055A1 (en) 2019-11-18 2020-11-18 Anti-ror-2 antibodies and methods of use

Publications (1)

Publication Number Publication Date
MX2022005949A true MX2022005949A (es) 2022-08-02

Family

ID=75981012

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005949A MX2022005949A (es) 2019-11-18 2020-11-18 Anticuerpos anti-ror-2 y metodos de uso.

Country Status (11)

Country Link
US (1) US20230192846A1 (es)
EP (1) EP4061848A4 (es)
JP (1) JP2023502108A (es)
KR (1) KR20220113951A (es)
CN (1) CN116018353A (es)
AU (1) AU2020388577A1 (es)
BR (1) BR112022009611A2 (es)
CA (1) CA3161617A1 (es)
IL (1) IL293026A (es)
MX (1) MX2022005949A (es)
WO (1) WO2021102055A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3953372A4 (en) * 2019-03-26 2022-11-02 The Regents of The University of California CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS (CAR-T) FOR THE TREATMENT OF HEMATOLOGICAL AND SOLID TUMORS
WO2023164618A1 (en) * 2022-02-25 2023-08-31 Bioatla, Inc. Cancer treatment with a conditionally active anti-ror2 antibody-drug conjugate

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009002522A (es) * 2006-09-08 2009-06-19 Genentech Inc Antagonistas de wnt y su uso en el diagnóstico y tratamiento de trastornos mediados por wnt.
GB201506407D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
EP3405494A1 (en) * 2016-01-20 2018-11-28 The Scripps Research Institute Ror2 antibody compositions and related methods
TW201805307A (zh) * 2016-05-13 2018-02-16 美商拜奧亞特拉公司 抗-ror2抗體、抗體片段、其免疫結合物及其用途
MX2018015592A (es) * 2016-06-14 2019-04-24 Xencor Inc Anticuerpos inhibidores de puntos de control biespecificos.
CA3099487A1 (en) * 2017-07-20 2019-01-24 Nbe-Therapeutics Ag Human antibodies binding to ror2

Also Published As

Publication number Publication date
CA3161617A1 (en) 2021-05-27
IL293026A (en) 2022-07-01
BR112022009611A2 (pt) 2022-08-09
US20230192846A1 (en) 2023-06-22
EP4061848A4 (en) 2024-03-20
JP2023502108A (ja) 2023-01-20
WO2021102055A1 (en) 2021-05-27
KR20220113951A (ko) 2022-08-17
AU2020388577A1 (en) 2022-06-02
CN116018353A (zh) 2023-04-25
EP4061848A1 (en) 2022-09-28

Similar Documents

Publication Publication Date Title
PE20091196A1 (es) Anticuerpos contra el vegf completamente humano, composiciones y metodos
CR20200579A (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
PE20191546A1 (es) Moleculas de union antigeno biespecificas que comprenden el clon 20h4.9 anti-41bb
JOP20180042A1 (ar) نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
CR11030A (es) Proteinas de union, incluyendo anticuerpos, derivados de anticuerpos y fragmentos de anticuerpos, que se unen especificamente a cd154 y sus usos
EA201590208A1 (ru) Усиление активности т-клеток car путем совместного введения биспецифического антитела
CO6430469A2 (es) Anticuerpos humanizados que se unen a cd19 y sus usos
EA202090800A1 (ru) Новые анти-cd3-эпсилон антитела
PE20120475A1 (es) Anticuerpos especificos para dkk-1
RU2018128414A (ru) Новое psma-связывающее антитело и его применения
RU2012128343A (ru) АНТИ-С4.4а АНТИТЕЛА И ИХ ПРИМЕНЕНИЕ
NZ597067A (en) Monoclonal antibodies expressed by ATCC PTA-4621 for the treatment of cancer
MX2022005949A (es) Anticuerpos anti-ror-2 y metodos de uso.
MX2020013606A (es) Constructos de anticuerpos multiespecificos.
PE20230374A1 (es) Anticuerpos dirigidos a un complejo que comprende hla-i no clasico y neoantigeno y sus metodos de uso
MX2022012182A (es) Metodos de uso de anticuerpos anti-trem2.
AR110967A1 (es) Anticuerpos miméticos fgf21 y su uso
RU2015147451A (ru) Использование о-ацетилированного gd2 ганглиозида в качестве мишени как новый терапевтический и диагностический подход при злокачественных новообразованиях, содержащих опухолевые стволовые клетки
PE20230839A1 (es) Agentes de union a lair-1 y metodos para su uso
EA202191231A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ЭНДОКРИННОЙ ОФТАЛЬМОПАТИИ С ПРИМЕНЕНИЕМ АНТИ-FcRn АНТИТЕЛ
ZA202008095B (en) Humanized antibodies against psma
PE20231504A1 (es) Anticuerpos especificos para kras y sus usos
CR20220288A (es) Anticuerpos contra integrina alfa 11 beta 1
MX2021003673A (es) Anticuerpos anti-vsig4 humano y usos de los mismos.
WO2022174103A3 (en) Monoclonal antibodies specific for human ror1